TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04419311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard® Knee System
Description: Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
Study: NCT02730195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor (TKI)
Description: Given TKI therapy
Study: NCT03354143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
Study: NCT03354143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
Study: NCT02847676

Intervention type: PROCEDURE
Intervention: Tissue sample donation
Description: Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.

Intervention type: PROCEDURE
Intervention: Tissue sample donation
Description: Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.

Intervention type: PROCEDURE
Intervention: Tissue sample donation
Description: Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.

Intervention type: PROCEDURE
Intervention: Tissue sample donation
Description: Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
Study: NCT01795768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 4547
Study: NCT02735824

Intervention type: PROCEDURE
Intervention: blood sampling and skin biopsy
Description: Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.

Intervention type: PROCEDURE
Intervention: blood sampling or mouth swap
Description: specimen will be used for genetic testing, results compared to patients

Intervention type: PROCEDURE
Intervention: blood sampling
Description: Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
Study: NCT00995033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX vaccine
Description: NicVAX vaccine given 6 times over 6 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
Study: NCT03246997

Intervention type: OTHER
Group type: OTHER
Intervention: Autumn Group
Description: The intervention is participating in a fruit and vegetable farm share for 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Spring Group
Description: The intervention is participating in a fruit and vegetable farm share for 6 months.
Study: NCT03636841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical device with CE marking (Ultravision ©)
Description: Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical device with CE marking (Ultravision ©)
Description: Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
Study: NCT02329340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Am Academy of Pediatrics print materials
Description: Print materials of injury prevention content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family safety 1-2-3
Description: Theoretically based school-aged childhood injury prevention videos for families
Study: NCT01239992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin/ Laropiprant
Description: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
Study: NCT02810444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgG Next Generation (BT595)
Study: NCT04427826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride
Description: A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
Study: NCT05154305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: * individually adjusted physical program consisting of strength and endurance training \> 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual.
Study: NCT02785770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Single oral dose of PF-04447943 administered as an extemporaneously prepared solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Single oral dose of PF-04447943 administered as an extemporaneously prepared solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose of moxifloxacin administered as tablet
Study: NCT01696162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm based Exercise Videos
Description: The algorithm will adjust the exercises in each session based upon the participant's feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDF Exercise Sheets
Description: A sheet of six exercises with descriptions on how to perform them properly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited Exercise Videos
Description: Video of 6 exercises that provide instruction on how to perform the exercises
Study: NCT01215929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
Study: NCT01594801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPad
Description: Use of the InsuPad for at least 3 times a day.
Study: NCT00855270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline will be used as placebo for control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Study: NCT03827044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
Study: NCT02879331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10 coils in upper lobes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 coils in upper and lower lobes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cycloergometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cycloergometry
Study: NCT02600871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provodine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision and Drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Study: NCT03537469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTU Mega 20 real device
Description: The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CTU Mega 20 sham device
Description: A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
Study: NCT01627834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Study: NCT04802629

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
Study: NCT01976039

Intervention type: OTHER
Group type: OTHER
Intervention: rhinopharyngeal retrograde clearance (RRC)
Description: The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rhinopharyngeal retrograde clearance (RRC)
Description: The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
Study: NCT01688206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab [TECENTRIQ]
Description: Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
Study: NCT03495609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle
Description: Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
Study: NCT00220779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Study: NCT00761020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No Intervention
Study: NCT00220779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 25%, United States Pharmacopeia (USP)
Study: NCT03561532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: FMT administered into the cecum of the patient in colonoscopy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
Study: NCT00639743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ( group B)
Description: placebo ( group B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase (group A)
Description: tenecteplase (group A)
Study: NCT00904410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: 370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
Study: NCT02935829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread as reference food
Description: Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carob snack as test food
Description: Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate cookie snack as test food
Description: Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carob preload
Description: Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate cookie preload
Description: Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
Study: NCT04642001

Intervention type: OTHER
Group type: OTHER
Intervention: Photon Laser III-DMC (without radiation emission) + My First- Colgate
Description: Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK
Description: Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Laser III-DMC (with irradiation emission) + My First- Colgate
Description: Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK
Description: Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
Study: NCT02226679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl-LVR
Description: Algisyl-LVR™ device (implants) administered during a surgical procedure
Study: NCT00476671

Intervention type: PROCEDURE
Intervention: lumbar puncture, MRI, MRS
Description: lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
Study: NCT00813943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide (2-times weekly)
Description: Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide (5-times weekly)
Description: Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
Study: NCT02404662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive text messages intervention
Description: The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
Study: NCT03717350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once